TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05489172

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Hola Bebe
Description: Participants will receive the handout It's never too early to prevent diabetes and will meet with the health educator at their CHC and download the Hola Bebe app. The health educator will advise participants to watch one module and complete an action plan for each of the first 12 weeks of study and encourage participants to weigh themselves weekly. The app includes the following features:1) educational/ behavioral audio visual modules, with automatic prompting to complete an action plan at the end of each module; 2) a motivational message library so that participants can chose which motivational texts they wish to receive, how often and time of day; 3) a community forum where participants can interact with each other and ask questions to the health educator; 4) tracking of weights to allow participants to see a graphic of their weight over time by inputting weekly weights; and 5) awards program where participants can earn badges for completing modules.
Study: NCT00108303

Intervention type: OTHER
Intervention: Diagnostic
Description: Diagnostic evaluation for schizophrenia. Schizophrenia includes schizophrenia and schizoaffective disorder.
Study: NCT04236024

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Board game
Description: The students in the experimental group will play board game to learn medication about 30-60 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional lecture
Description: The students in the comparison group will receive medication lecture using PPT slides about 30-60 minutes.
Study: NCT01685801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: 150 milligram (mg) tablet orally every 12 hours up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: 150 milligram (mg) tablet orally every 12 hours up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: 150 milligram (mg) tablet orally every 12 hours up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: 150 milligram (mg) tablet orally every 12 hours up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matched-to-ivacaftor tablet
Description: Orally every 12 hours up to 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matched-to-ivacaftor tablet
Description: Orally every 12 hours up to 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matched-to-ivacaftor tablet
Description: Orally every 12 hours up to 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matched-to-ivacaftor tablet
Description: Orally every 12 hours up to 4 weeks.
Study: NCT04261400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAMAACT
Description: Improved communication regarding warning signs of pregnancy complications
Study: NCT01019343

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arm Intellistretch Device
Description: The purpose of the Arm Intellistretch device is to objectively quantify wrist tone. It is used for rehabilitation applications in hospitals and office settings. Currently, rigidity is evaluated clinically using a subjective scale, zero to four and is part of the UPDRS. The Arm Intellistretch device is manufactured by Rehabtek, Inc., is FDA approved, and has been determined to be a non-significant risk device by the CNS IRB.
Study: NCT03368053

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood samples will be taken during the single study visit at Year 14 for the assessment of: HIV testing, antibody determination, cell mediated immune (CMI) responses and exploratory characterisation.
Study: NCT02576041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine
Description: Bilastine tablets once a day for 7+3 days
Study: NCT01019343

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Sonography (TCS)
Description: Transcranial sonography will be conducted by a physician in the Clinical Center using the Acuson Antares ultrasound machine. This techniques uses ultrasound signals to image the brain. It entails having the subject sit in a chair or lay in a bed while the sonographer places a lubricated 2-inch ultrasound probe over the skin of the temporal area just above the patient s ear. Ultrasound images are then recorded. The procedure is not invasive and will last about 45 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Sonography (TCS)
Description: Transcranial sonography will be conducted by a physician in the Clinical Center using the Acuson Antares ultrasound machine. This techniques uses ultrasound signals to image the brain. It entails having the subject sit in a chair or lay in a bed while the sonographer places a lubricated 2-inch ultrasound probe over the skin of the temporal area just above the patient s ear. Ultrasound images are then recorded. The procedure is not invasive and will last about 45 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral tasks
Description: To assess the changes in cerebral physiology in the brain, subjects will be presented sensory stimuli (e.g., primary visual stimulation with flashing lights or checkerboard, auditory with tone or speech, or olfactory stimuli), or will be asked to perform non-exercise motor tasks (e.g., tapping of fingers, squeezing ball, moving joystick), to perform cognitive tasks such as a working memory task (e.g., n-back with or without catch rules, word finding), or to just rest or sleep.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral tasks
Description: To assess the changes in cerebral physiology in the brain, subjects will be presented sensory stimuli (e.g., primary visual stimulation with flashing lights or checkerboard, auditory with tone or speech, or olfactory stimuli), or will be asked to perform non-exercise motor tasks (e.g., tapping of fingers, squeezing ball, moving joystick), to perform cognitive tasks such as a working memory task (e.g., n-back with or without catch rules, word finding), or to just rest or sleep.
Study: NCT02576041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets once a day during 7+3 days run in period
Study: NCT01159925

Intervention type: PROCEDURE
Intervention: Serum sample
Description: Serum samples collected

Intervention type: PROCEDURE
Intervention: Serum sample
Description: Serum samples collected

Intervention type: PROCEDURE
Intervention: Serum sample
Description: Serum samples collected
Study: NCT04052763

Intervention type: DIAGNOSTIC_TEST
Intervention: FFR-CT
Description: FFR-CT is a non invasive method using coronary CT images and 3 dimensional modelling to reconstruct coronary arteries and their stenoses, with subsequent calculation of fractional flow reserve (FFR) based on a mathematical algorithm.
Study: NCT01640951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457 300 mg
Description: Secukinumab 150 mg (2 injections per dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457 300 mg
Description: Secukinumab 150 mg (2 injections per dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02776982

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Confocal endomicroscopy
Description: Confocal endomicroscopy will be performed during clinically indicated endoscopy.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mucosal impedance
Description: Mucosal impedance will be performed at the time of clinically indicated endoscopy.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Research biopsies
Description: Research biopsies will be obtained during clinically indicated endoscopy.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bravo ambulatory pH monitor
Description: Bravo ambulatory pH capsule will be placed during clinically indicated endoscopy.
Study: NCT03989310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Manganese Chloride
Description: Administered by inhalation at 0.4mg/kg twice per week in a 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Administered intravenously, 200mg/d on day 1 and day 8 in a 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Administered intravenously, 200mg/d on day 1 and day 8 in a 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered intravenously, 1g/m2/d on day1 and day8 in a 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered intravenously, 1g/m2/d on day1 and day8 in a 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-1 antibody
Description: Administered intravenously, 2-4mg/kg on day 2 in a 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-1 antibody
Description: Administered intravenously, 2-4mg/kg on day 2 in a 3-week cycle
Study: NCT00592891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Description: Total body pressurized oxygen
Study: NCT00916409

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-100A device
Description: patients will be treated continuously with the NovoTTF-100A device, in addition to Temozolomide. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: maintenance Temozolomide will be administered according to the approved dosing scheme as follows: Maintenance Phase Cycle 1: Four weeks after completing the Temozolomide + Radiotherapy phase, Temozolomide is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m2 once daily for 5 days followed by 23 days without treatment.~Cycles 2-6: At the start of Cycle 2, the dose is escalated to 200 mg/m2, if the CTC non-hematologic toxicity for Cycle 1 is Grade ≤2 (except for alopecia, nausea and vomiting), absolute neutrophil count (ANC) is ≥ 1.5 x 109/L, and the platelet count is ≥ 100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs. If the dose was not escalated at Cycle 2, escalation should not be done in subsequent cycles.
Study: NCT01220869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix was given as subcutaneous (s.c.) injections with a 240 mg starting dose followed one month later by a 80 mg maintenance dose. The maintenance dosing was repeated for an additional 5 months (total treatment period was 168 days).
Study: NCT02449785

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR measurements of lung morphological changes in cystic fibrosis (Avanto dot, Siemens)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT measurements of lung morphological changes in cystic fibrosis
Study: NCT03120026

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental product
Description: Two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Isocaloric placebo
Description: Two servings (40 grams each) of an isocaloric (maltodextrins) powder which has to be dissolved in 125 ml of water.
Study: NCT03695549

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAF + (A-PRF)
Description: advanced platelet rich fibrin prepared by low speed centrfugation concept(LSCC) together with coronally advanced flap .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAF+SCTG
Description: cornally advanced flap plus subepithilial connective tissue graft harvested from the palate
Study: NCT04284085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Description: Psycho-educational groups of 10 to 12 people, led by two professionals, one of them will always be a psychologist and an educator. In some sessions, other collaborators will be invited to participate, such as psychiatrists, educators, social workers, etc. who may act as external observers or implement the session. The number of sessions will be 13, one or two sessions a week and duration of 90 minutes.
Study: NCT03336892

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Health Care Coordination
Description: Enhanced usual care with written mental health resources and system navigation information in addition to individualized mental health care coordination by a dedicated specially trained mental health care coordinator.
Study: NCT04031794

Intervention type: DEVICE
Intervention: Extra Corporeal Membrane Oxygenator (ECMO)
Description: Two cannular will be inserted via femoral vein or internal jugular vein and connect with blood pump and membrane oxygenation.
Study: NCT04539015

Intervention type: DEVICE
Intervention: Prevena Plus
Description: PREVENA Plus is a negative pressure wound therapy device intended for use on surgical incisions that continue to drain following sutured or stapled closures.
Study: NCT01357512

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging, Siemens
Description: Magnetic resonance imaging (MRI) of prostate with Siemens 3-tesla device
Study: NCT00523419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m\^2, IV every 21 days until disease progression, unacceptable toxicity, participant or physician's decision.
Study: NCT02507505

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional Anesthesia
Description: Regional anesthesia involves temporarily numbing parts of the body with nerve blocks. Spinal anesthesia is a type of regional anesthesia that uses medications injected into the fluid surrounding the spinal cord to temporarily numb the legs and lower abdomen. Spinal anesthesia is the most widely used type of regional anesthesia for hip fracture surgery. While intravenous sedation is typically used for comfort with spinal anesthesia, invasive airway interventions are not typically required.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: General anesthesia uses injected or inhaled medications to keep people unconscious during surgery. Since general anesthesia depresses breathing and impairs protective airway reflexes, invasive airway interventions such as breathing tube placement and mechanical ventilation are usually required.
Study: NCT04153240

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Night Shift™ Sleep Positioner (Advanced Brain Monitoring, USA)
Description: The Night Shift™ Sleep Positioner (Advanced Brain Monitoring, USA) has been developed for adult patients with positional OSA, and snorers. Worn on the back of the neck, it begins to vibrate when the patient starts to sleep in the supine position and increases in intensity until the patient changes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: The Night Shift™ Sleep Positioner (Advanced Brain Monitoring, USA)
Description: The Night Shift™ Sleep Positioner (Advanced Brain Monitoring, USA) has been developed for adult patients with positional OSA, and snorers. Worn on the back of the neck, it begins to vibrate when the patient starts to sleep in the supine position and increases in intensity until the patient changes.
Study: NCT04525664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500mg
Description: 500 mg per os twice daily for 14 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 1000 MG
Description: 1000 mg per os twice daily for 14 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 MG
Description: 40 mg per os twice daily for 14 consecutive days.
Study: NCT01401218

Intervention type: OTHER
Intervention: Electronic Medical Record (EMR) Review
Description: measurements of potential risk factors of acute kidney injury through the patients' previous medical record review.~potential risk factors include previous history of hypertension, diabetes, cerebrovascular events, peripheral arterial disease, chronic obstructive pulmonary disease, recent myocardial infarction, coronary artery disease; preoperative glomerular filtration rate, preoperative creatinine level, preoperative cardiac ejection fraction reported on echocardiography, use of preoperative inotropics, use of deep hypothermic cardiac arrest, intraoperative colloid use, intraoperative blood product transfusion, total time of cardiopulmonary bypass,
Study: NCT01065649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Description: It will be administered per oral 10 mg a day in the first 7 days and then 25 mg a day in the last 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nortriptyline
Description: It will be administered per oral 10 mg a day in the first 7 days and then 25 mg a day in the last 14 days
Study: NCT04052763

Intervention type: DIAGNOSTIC_TEST
Intervention: FFRangio™
Description: Angiography-derived FFR (FFRangio™) uses coronary angiography images and a mathematical algorithm to reconstruct a 3 dimensional model of coronary arteries with calculation of FFR without the use of a pressure guide.
Study: NCT00227669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study: NCT01065649

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo arm
Description: Placebo per oral for 21 days, equal to nortriptyline
Study: NCT03901781

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ST266 via Intranasal Delivery
Description: ST266 administered by non-invasive trans-cribriform intranasal delivery using the SipNose intranasal device.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ST266 via Intranasal Delivery
Description: ST266 administered by non-invasive trans-cribriform intranasal delivery using the SipNose intranasal device.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ST266 via Intranasal Delivery
Description: ST266 administered by non-invasive trans-cribriform intranasal delivery using the SipNose intranasal device.
Study: NCT01019343

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TMS single/paired pulse
Description: For MEP acquisition during TMS, electrodes will be placed over the belly and the tendon of the distal muscles of the hand or foot and/or proximal muscles (see sub-section EMG 7.1.3.1 for the details of the procedure).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TMS single/paired pulse
Description: For MEP acquisition during TMS, electrodes will be placed over the belly and the tendon of the distal muscles of the hand or foot and/or proximal muscles (see sub-section EMG 7.1.3.1 for the details of the procedure).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: MEG
Description: MEG recordings will be performed together with experienced personnel in the NIMH MEG lab in the NMR center in Building 10. For these recording sessions, subjects will sit in a chair or lay down with a helmet placed over the head. The helmet used for MEG does not require the application of conductive gel. Scan times vary from 20 minutes to 2 hours.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MEG
Description: MEG recordings will be performed together with experienced personnel in the NIMH MEG lab in the NMR center in Building 10. For these recording sessions, subjects will sit in a chair or lay down with a helmet placed over the head. The helmet used for MEG does not require the application of conductive gel. Scan times vary from 20 minutes to 2 hours.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: EEG
Description: EEGs will be recorded by, or together with, experienced personnel in the HMCS EEG lab in Building 10, or in the NMR center.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EEG
Description: EEGs will be recorded by, or together with, experienced personnel in the HMCS EEG lab in Building 10, or in the NMR center.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: MRI techniques
Description: MRI sub-studies will be conducted on 3.0 T or 7T units in the NMR Research Center. All volunteers will comply with the yearly requirement of a standard clinical diagnostic MRI scan of the head performed at 3.0T, to be submitted to the Diagnostic Radiology Department of the Clinical Center for interpretation. If the subject does not have a clinical scan performed within 12 month of the exam, a standard clinical MRI will be performed and reviewed before the research MR. The standard examination takes approximately 15 minutes to complete; after that, the research MR scans will be performed. Standard clinical MRI of the head will be repeated on an annual basis and read by the Diagnostic Radiology Department of the Clinical Center.
Study: NCT04291027

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Land Based Exercise
Description: Group exercise intervention will be held 2 times per week for 12 weeks and will include balance training, strengthening, gait training, and cardiovascular training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic Exercise
Description: Group exercise intervention will be held 2 times per week for 12 weeks and will include balance training, strengthening, gait training, and cardiovascular training.
Study: NCT01354574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Glycemic Index meals
Description: Dietary intervention with meals containing high glycemic index carbohydrates. All foods provided to meet the individual's energy needs. Standardized test meal (breakfast)also contained only high glycemic index carbohydrates and energy content was adjusted for each individual, providing 40% of daily energy needs.
Study: NCT01354574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index meals
Description: Dietary intervention with meals containing low glycemic index carbohydrates. All foods provided to meet the individual's energy needs. Standardized test meal (breakfast)also contained only low glycemic index carbohydrates and energy content was adjusted for each individual, providing 40% of daily energy needs.